Difference between revisions of "ALK translocation renal cell carcinoma"
Jump to navigation
Jump to search
(infobox) |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 14: | Line 14: | ||
| IF = | | IF = | ||
| Gross = | | Gross = | ||
| Grossing = | | Grossing = [[total nephrectomy for tumour grossing]], [[partial nephrectomy grossing]] | ||
| Staging = | | Staging = [[kidney cancer staging]] | ||
| Site = [[kidney]] - see ''[[kidney tumours]]'' | | Site = [[kidney]] - see ''[[kidney tumours]]'' | ||
| Assdx = | | Assdx = | ||
| Line 61: | Line 61: | ||
*CK7 +ve (focal). | *CK7 +ve (focal). | ||
*[[SMARCB1]] normal nuclear staining.{{fact}} | *[[SMARCB1]] normal nuclear staining.{{fact}} | ||
==Molecular== | |||
*ALK rearrangement. | |||
==See also== | ==See also== | ||
Latest revision as of 14:39, 16 December 2024
| ALK translocation renal cell carcinoma | |
|---|---|
| Diagnosis in short | |
|
| |
| LM | mixed morphology, +/-papillae, +/-myxoid change |
| LM DDx | papillary renal cell carcinoma, unclassified renal cell carcinoma, clear cell renal cell carcinoma, SMARCB1-deficient renal medullary carcinoma |
| IHC | ALK +ve |
| Molecular | ALK rearranagement |
| Grossing notes | total nephrectomy for tumour grossing, partial nephrectomy grossing |
| Staging | kidney cancer staging |
| Site | kidney - see kidney tumours |
|
| |
| Prevalence | very rare |
| Treatment | may respond to ALK inhibitors |
ALK translocation renal cell carcinoma, also ALK-rearranged renal cell carcinoma and ALK-positive renal cell carcinoma, is a type of renal cell carcinoma recognized by the WHO.
General
- Extremely rare.
- May respond to ALK inhibitors such as alectinib[4] or crizotinib.[3]
Microscopic
Features:
- Mix of morphologies - including:
DDx:
- Papillary renal cell carcinoma - especially what used to be known as "type 2".[1]
- Unclassified renal cell carcinoma
- Renal medullary carcinoma.
- Clear cell renal cell carcinoma.[2]
IHC
Features:[6]
- ALK +ve.
- PAX8 +ve.
- Vimentin +ve (diffuse).
- CK7 +ve (focal).
- SMARCB1 normal nuclear staining.[citation needed]
Molecular
- ALK rearrangement.
See also
References
- ↑ 1.0 1.1 1.2 Lee, C.; Park, JW.; Suh, JH.; Nam, KH.; Moon, KC. (Oct 2013). "ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients.". Korean J Pathol 47 (5): 452-7. doi:10.4132/KoreanJPathol.2013.47.5.452. PMID 24255633.
- ↑ 2.0 2.1 Doğan K, Onder E (January 2024). "ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey". Pathol Res Pract 253: 154951. doi:10.1016/j.prp.2023.154951. PMID 38039739.
- ↑ 3.0 3.1 Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.
- ↑ Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.
- ↑ Kuroda, N.; Karashima, T.; Inoue, K.; Kasajima, A.; Ohe, C.; Kawakami, F.; Mikami, S.; Matsuura, K. et al. (Mar 2015). "Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects.". Pol J Pathol 66 (1): 3-8. PMID 26017874.
- ↑ Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.